|
1
|
Tew WP: Ovarian cancer in the older woman.
J Geriatr Oncol. 7:354–361. 2016.
|
|
2
|
Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin
WZ, Wu SC and Lai YL: Risk of ovarian cancer in women with pelvic
inflammatory disease: A population-based study. Lancet Oncol.
12:900–904. 2011.
|
|
3
|
Kurman RJ and Shih IeM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010.
|
|
4
|
Colombo N: Optimizing treatment of the
partially platinum-sensitive ovarian cancer patient. Future Oncol.
9(Suppl): 19–23. 2013.
|
|
5
|
Gershenson DM: Treatment of ovarian cancer
in young women. Clin Obstet Gynecol. 55:65–74. 2012.
|
|
6
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al Cancer
Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011.
|
|
7
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011.
|
|
8
|
Bookman MA: First-line chemotherapy in
epithelial ovarian cancer. Clin Obstet Gynecol. 55:96–113.
2012.
|
|
9
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj
A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E,
Cruickshank D, et al: Ovarian cancer screening and mortality in the
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A
randomised controlled trial. Lancet. 387:945–956. 2016.
|
|
10
|
Bagnoli M, Pignata S and Mezzanzanica D: A
miRNA signature assessing ovarian cancer prognosis. Oncoscience.
3:308–310. 2016.
|
|
11
|
Kan CW, Howell VM, Hahn MA and Marsh DJ:
Genomic alterations as mediators of miRNA dysregulation in ovarian
cancer. Genes Chromosomes Cancer. 54:1–19. 2015.
|
|
12
|
Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X,
Xie D, Shen Z, Sze J, Li K, et al: MYC protein inhibits
transcription of the microRNA cluster MC-let-7a-1~let-7d via
noncanonical E-box. J Biol Chem. 286:39703–39714. 2011.
|
|
13
|
Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang
YC, Lu SW, Yu CH, Huang HS, Wang JJ, Tsai CH, et al: Let-7d
functions as novel regulator of epithelial-mesenchymal transition
and chemoresistant property in oral cancer. Oncol Rep.
26:1003–1010. 2011.
|
|
14
|
Sun H, Ding C, Zhang H and Gao J: Let-7
miRNAs sensitize breast cancer stem cells to radiation-induced
repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling
pathway. Mol Med Rep. 14:3285–3292. 2016.
|
|
15
|
Rohm B, Holik AK, Kretschy N, Somoza MM,
Ley JP, Widder S, Krammer GE, Marko D and Somoza V: Nonivamide
enhances miRNA let-7d expression and decreases adipogenesis PPARγ
expression in 3T3-L1 cells. J Cell Biochem. 116:1153–1163.
2015.
|
|
16
|
García-Vázquez R, Gallardo Rincón D,
Ruiz-García E, Meneses García A, Hernández De La Cruz ON,
Astudillo-De La Vega H, Isla-Ortiz D, Marchat LA, Salinas-Vera YM,
Carlos-Reyes Á, et al: let-7d-3p is associated with apoptosis and
response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep.
39:3086–3094. 2018.
|
|
17
|
Ye H, Chen J, Huang X, Guo A and Hao P:
Construction of let-7d expression vector and its inhibitory effect
on HMGA2 and ras expression in human ovarian cancer cells in vitro.
Nan Fang Yi Ke Da Xue Xue Bao. 32:1752–1757. 2012.In Chinese.
|
|
18
|
Zhou J, Xie M, He H, Shi Y, Luo B, Gong G,
Li J, Wang J, Wu X and Wen J: Increases urinary HMGA1 in serous
epithelial ovarian cancer patients. Cancer Biomark. 15:325–331.
2015.
|
|
19
|
Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW,
Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, et al: Crucial role
of HMGA1 in the self-renewal and drug resistance of ovarian cancer
stem cells. Exp Mol Med. 48:e2552016.
|
|
20
|
Puca F, Colamaio M, Federico A, Gemei M,
Tosti N, Bastos AU, Del Vecchio L, Pece S, Battista S and Fusco A:
HMGA1 silencing restores normal stem cell characteristics in colon
cancer stem cells by increasing p53 levels. Oncotarget.
5:3234–3245. 2014.
|
|
21
|
Aiello A, Pandini G, Sarfstein R, Werner
H, Manfioletti G, Vigneri R and Belfiore A: HMGA1 protein is a
positive regulator of the insulin-like growth factor-I receptor
gene. Eur J Cancer. 46:1919–1926. 2010.
|
|
22
|
Fraser JA, Madhumalar A, Blackburn E,
Bramham J, Walkinshaw MD, Verma C and Hupp TR: A novel p53
phos-phorylation site within the MDM2 ubiquitination signal: II. a
model in which phosphorylation at SER269 induces a mutant
conformation to p53. J Biol Chem. 285:37773–37786. 2010.
|
|
23
|
Stegh AH: Targeting the p53 signaling
pathway in cancer therapy - the promises, challenges and perils.
Expert Opin Ther Targets. 16:67–83. 2012.
|
|
24
|
Woo MG, Xue K, Liu J, McBride H and Tsang
BK: Calpain-mediated processing of p53-associated parkin-like
cytoplasmic protein (PARC) affects chemosensitivity of human
ovarian cancer cells by promoting p53 subcellular trafficking. J
Biol Chem. 287:3963–3975. 2012.
|
|
25
|
Wilking MJ, Singh C, Nihal M, Zhong W and
Ahmad N: SIRT1 deacetylase is overexpressed in human melanoma and
its small molecule inhibition imparts anti-proliferative response
via p53 activation. Arch Biochem Biophys. 563:94–100. 2014.
|
|
26
|
Marx C, Marx-Blümel L, Lindig N, Thierbach
R, Hoelzer D, Becker S, Wittig S, Lehmann R, Slevogt H, Heinzel T,
et al: The sirtuin 1//2 inhibitor tenovin-1 induces a nonlinear
apoptosis-inducing factor-dependent cell death in a p53 null
Ewing’s sarcoma cell line. Invest New Drugs. 36:396–406. 2018.
|
|
27
|
Grbesa I, Pajares MJ, Martínez-Terroba E,
Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio
R and Montuenga LM: Expression of sirtuin 1 and 2 is associated
with poor prognosis in non-small cell lung cancer patients. PLoS
One. 10:e01246702015.
|
|
28
|
Ayuk SM, Abrahamse H and Houreld NN: The
role of photo-biomodulation on gene expression of cell adhesion
molecules in diabetic wounded fibroblasts in vitro. J Photochem
Photobiol B. 161:368–374. 2016.
|
|
29
|
Garces AH, Dias MS, Paulino E, Ferreira CG
and de Melo AC: Treatment of ovarian cancer beyond chemotherapy:
Are we hitting the target? Cancer Chemother Pharmacol. 75:221–234.
2015.
|
|
30
|
Gu A, Jie Y, Yao Q, Zhang Y and Mingyan E:
Slug is associated with tumor metastasis and angiogenesis in
ovarian cancer. Reprod Sci. 24:291–299. 2017.
|
|
31
|
Nuovo GJ, Garofalo M, Valeri N, Roulstone
V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A,
et al: Reovirus-associated reduction of microRNA-let-7d is related
to the increased apoptotic death of cancer cells in clinical
samples. Mod Pathol. 25:1333–1344. 2012.
|
|
32
|
Anfray C, Dong B, Komaty S, Mintova S and
Valable S: Acute toxicity of silver free and encapsulated in
nanosized zeolite for eukaryotic cells. ACS Appl Mater Interfaces.
9:13849–13854. 2017.
|
|
33
|
Milatz S, Himmerkus N, Wulfmeyer VC,
Drewell H, Mutig K, Hou J, Breiderhoff T, Müller D, Fromm M, Bleich
M, et al: Mosaic expression of claudins in thick ascending limbs of
Henle results in spatial separation of paracellular Na+
and Mg2+ transport. Proc Natl Acad Sci USA.
114:E219–E227. 2017.
|
|
34
|
Yang J, Zhang Q, Dong JQ, Chang XH and He
XJ: Overexpression of high mobility group A2 and its correlation
with microRNA let-7 family in serous ovarian cancers. Beijing Da
Xue Xue Bao Yi Xue Ban. 44:749–754. 2012.In Chinese.
|
|
35
|
Sterenczak KA, Eckardt A, Kampmann A,
Willenbrock S, Eberle N, Länger F, Kleinschmidt S,
Hewicker-Trautwein M, Kreipe H, Nolte I, et al: HMGA1 and HMGA2
expression and comparative analyses of HMGA2, Lin28 and let-7
miRNAs in oral squamous cell carcinoma. BMC Cancer. 14:6942014.
|
|
36
|
Ramberg H, Alshbib A, Berge V, Svindland A
and Taskén KA: Regulation of PBX3 expression by androgen and Let-7d
in prostate cancer. Mol Cancer. 10:502011.
|
|
37
|
Ning YX, Luo X, Xu M, Feng X and Wang J:
Let-7d increases ovarian cancer cell sensitivity to a genistein
analog by targeting c-Myc. Oncotarget. 8:74836–74845. 2017.
|
|
38
|
Pandit KV, Corcoran D, Yousef H,
Yarlagadda M, Tzouvelekis A, Gibson KF, Konishi K, Yousem SA, Singh
M, Handley D, et al: Inhibition and role of let-7d in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 182:220–229.
2010.
|
|
39
|
Kobayashi M, Salomon C, Tapia J, Illanes
SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is
associated with discordant exosomal sequestration of Let-7 miRNA
and miR-200. J Transl Med. 12:42014.
|
|
40
|
Huang R, Huang D, Dai W and Yang F:
Overexpression of HMGA1 correlates with the malignant status and
prognosis of breast cancer. Mol Cell Biochem. 404:251–257.
2015.
|
|
41
|
Pegoraro S, Ros G, Piazza S, Sommaggio R,
Ciani Y, Rosato A, Sgarra R, Del Sal G and Manfioletti G: HMGA1
promotes metastatic processes in basal-like breast cancer
regulating EMT and stemness. Oncotarget. 4:1293–1308. 2013.
|
|
42
|
Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F,
Guo Z, Zhang X, Liu J, Shen Q, et al: Let-7d suppresses growth,
metastasis, and tumor macrophage infiltration in renal cell
carcinoma by targeting COL3A1 and CCL7. Mol Cancer. 13:2062014.
|
|
43
|
Suh YA, Post SM, Elizondo-Fraire AC,
Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T and
Lozano G: Multiple stress signals activate mutant p53 in vivo.
Cancer Res. 71:7168–7175. 2011.
|
|
44
|
Wang J, Gao Q and Li Q: Adenovirus type 12
E1B 55-kilo-dalton oncoprotein promotes p53-mediated apoptotic
response of ovarian cancer to cisplatin. Tumour Biol. 36:6569–6577.
2015.
|
|
45
|
Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao
XY, Liu L, Deng HX, Li J, Nie CL, et al: The p53 upregulated
modulator of apoptosis (PUMA) chemosensitizes intrinsically
resistant ovarian cancer cells to cisplatin by lowering the
threshold set by Bcl-x(L) and Mcl-1. Mol Med. 17:1262–1274.
2011.
|
|
46
|
Zhang X, Wu H, Liu C, Tian J and Qu L:
PI3K/Akt/p53 pathway inhibits reovirus infection. Infect Genet
Evol. 34:415–422. 2015.
|
